Pyxis Oncology Inc
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.
Current Price
$2.74
+21.24%Pyxis Oncology Inc (PYXS) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Pyxis Oncology Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $13.86M. Gross profit (TTM) is $11.47M. EBITDA is $-72.90M. Earnings per share (EPS) is $-1.28. The P/E ratio is -2.14. Market capitalization is $170.60M.
Free cash flow (FCF) is $-63.51M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Pyxis Oncology Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
